Letter
作者: Hsieh, James J ; Taylor, Matthew H ; Pinto, Alvaro ; Krohn Tennøe, Øyvind ; Gunnestad Ribe, Sara ; Lee Cohn, Allen ; Yogesh Shah, Amishi ; Kubiak, Peter ; Lee, Chung-Han ; Okpara, Chinyere E ; Bock, Daena ; Perini, Rodolfo ; Di Simone, Christopher ; Motzer, Robert J ; Gironés Sarrió, Regina ; Asim Bilen, Mehmet ; Rao, Arpit ; Courtright, Jay ; Heinrich, Daniel ; Sweis, Randy F ; Richards, Donald
The antitumor activity and safety of lenvatinib plus pembrolizumab (LEN + PEM) for the treatment of clear cell renal cell carcinoma (RCC) were first assessed in Study 111/KEYNOTE-146, a phase 1b/2 trial in multiple solid tumor types.Here we report results for 104 ICI-pretreated patients with clear cell RCC from Study 111/KEYNOTE-146 with an addnl. 24 mo of follow-up (final database lock date was August 24, 2022), for median survival follow-up of 34.5 mo (95% confidence interval [CI] 32.6-37.3).Patients were treated with lenvatinib 20 mg/d plus pembrolizumab 200 mg once every 3 wk, with a maximum of 35 pembrolizumab treatments.It is unknown whether these results can be extrapolated to PD-1 inhibitors and other TKIs; however, other studies in ICI-pretreated patients are ongoing.